Deerfield Management Company, L.P. (Series C) Erasca, Inc. Transaction History

Deerfield Management Company, L.P. (Series C)

$5.38 Billion
Q3 2024

2 transactions

Quarter	Operation	Price Per share	shares change	shares Held	SEC Form
Q4 2021 Feb 14, 2022	SELL	$12.51 - $22.75 $9.84 Million - $17.9 Million	-786,660 Closed	0 $0
Q3 2021 Nov 15, 2021	BUY	$17.43 - $24.34 $13.7 Million - $19.1 Million	786,660 New	786,660 $16.7 Million

Others Institutions Holding ERAS

# of Institutions

141

Shares Held

229M

Call Options Held

28.7K

Put Options Held

117K

Frazier Life Sciences Management, L.P. Menlo Park, CA

19.4M
Shares

$57.4 Million
2.85% of portfolio
T. Rowe Price Investment Management, Inc. Baltimore, MD

16.8M
Shares

$49.8 Million
0.03% of portfolio
Vr Adviser, LLC New York, NY

16.2M
Shares

$48 Million
4.58% of portfolio
Suvretta Capital Management, LLC New York, NY

13.8M
Shares

$40.8 Million
1.48% of portfolio
Vanguard Group Inc Valley Forge, PA

13.3M
Shares

$39.3 Million
0.0% of portfolio

View Full List

About Erasca, Inc.

Ticker ERAS
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 122,147,000
Market Cap $362M
Description
Erasca, Inc., a clinical-stage biopharmaceutical company, focuses on discovering, developing, and commercializing therapies for patients with RAS/MAPK pathway-driven cancers. The company's lead candidates include ERAS-007, an oral inhibitor of ERK1/2 for the treatment of non-small cell lung cancer, colorectal cancer, and acute myeloid leukemia; ...

More about ERAS

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Deerfield Management Company, L.P. (Series C), based on Form 13F filings with the SEC.

News

Stay updated on Deerfield Management Company, L.P. (Series C) with notifications on news.

Account